BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 34181850)

  • 1. Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
    Liang X; Sun C; Li C; Yu H; Wei X; Liu X; Bao W; Shi Y; Sun X; Khamrakulov M; Yang C; Liu H
    J Med Chem; 2021 Jul; 64(13):9217-9237. PubMed ID: 34181850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of Potent MALT1 Inhibitors Featuring a Novel "2-Thioxo-2,3-dihydrothiazolo[4,5-
    Liang X; Yu H; Liang R; Feng Z; Saidahmatov A; Sun C; Ren H; Wei X; Zhao J; Yang C; Liu H
    J Med Chem; 2024 Feb; 67(4):2884-2906. PubMed ID: 38349664
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-aryl-piperidine-4-carboxamides as a novel class of potent inhibitors of MALT1 proteolytic activity.
    Schlapbach A; Revesz L; Pissot Soldermann C; Zoller T; Régnier CH; Bornancin F; Radimerski T; Blank J; Schuffenhauer A; Renatus M; Erbel P; Melkko S; Heng R; Simic O; Endres R; Wartmann M; Quancard J
    Bioorg Med Chem Lett; 2018 Jul; 28(12):2153-2158. PubMed ID: 29759726
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALT1 inhibitors prevent the development of DSS-induced experimental colitis in mice via inhibiting NF-κB and NLRP3 inflammasome activation.
    Liu W; Guo W; Hang N; Yang Y; Wu X; Shen Y; Cao J; Sun Y; Xu Q
    Oncotarget; 2016 May; 7(21):30536-49. PubMed ID: 27105502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting BCL10 by small peptides for the treatment of B cell lymphoma.
    Bao W; Sun C; Sun X; He M; Yu H; Yan W; Wen F; Zhang L; Yang C
    Theranostics; 2020; 10(25):11622-11636. PubMed ID: 33052237
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of β-Lapachone Analogs as Novel MALT1 Inhibitors To Treat an Aggressive Subtype of Diffuse Large B-Cell Lymphoma.
    Lim SM; Jeong Y; Lee S; Im H; Tae HS; Kim BG; Park HD; Park J; Hong S
    J Med Chem; 2015 Nov; 58(21):8491-502. PubMed ID: 26496175
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery and optimization of cyclohexane-1,4-diamines as allosteric MALT1 inhibitors.
    Schiesser S; Hajek P; Pople HE; Käck H; Öster L; Cox RJ
    Eur J Med Chem; 2022 Jan; 227():113925. PubMed ID: 34742013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL.
    Fontan L; Goldstein R; Casalena G; Durant M; Teater MR; Wilson J; Phillip J; Xia M; Shah S; Us I; Shinglot H; Singh A; Inghirami G; Melnick A
    Blood; 2021 Feb; 137(6):788-800. PubMed ID: 32785655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autocleavage of the paracaspase MALT1 at Arg-781 attenuates NF-κB signaling and regulates the growth of activated B-cell like diffuse large B-cell lymphoma cells.
    Wu CH; Yang YH; Chen MR; Tsai CH; Cheng AL; Doong SL
    PLoS One; 2018; 13(6):e0199779. PubMed ID: 29953499
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo.
    Fontan L; Yang C; Kabaleeswaran V; Volpon L; Osborne MJ; Beltran E; Garcia M; Cerchietti L; Shaknovich R; Yang SN; Fang F; Gascoyne RD; Martinez-Climent JA; Glickman JF; Borden K; Wu H; Melnick A
    Cancer Cell; 2012 Dec; 22(6):812-24. PubMed ID: 23238016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and optimization of a series of small-molecule allosteric inhibitors of MALT1 protease.
    Lu T; Connolly PJ; Philippar U; Sun W; Cummings MD; Barbay K; Gys L; Van Nuffel L; Austin N; Bekkers M; Shen F; Cai A; Attar R; Meerpoel L; Edwards J
    Bioorg Med Chem Lett; 2019 Dec; 29(23):126743. PubMed ID: 31678006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and structure-activity relationship studies of MI-2 analogues as MALT1 inhibitors.
    Wu G; Wang H; Zhou W; Zeng B; Mo W; Zhu K; Liu R; Zhou J; Chen C; Chen H
    Bioorg Med Chem; 2018 Jul; 26(12):3321-3344. PubMed ID: 29751989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MALT1-dependent cleavage of CYLD promotes NF-κB signaling and growth of aggressive B-cell receptor-dependent lymphomas.
    Minderman M; Lantermans HC; Grüneberg LJ; Cillessen SAGM; Bende RJ; van Noesel CJM; Kersten MJ; Pals ST; Spaargaren M
    Blood Cancer J; 2023 Mar; 13(1):37. PubMed ID: 36922488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth.
    Fontán L; Qiao Q; Hatcher JM; Casalena G; Us I; Teater M; Durant M; Du G; Xia M; Bilchuk N; Chennamadhavuni S; Palladino G; Inghirami G; Philippar U; Wu H; Scott DA; Gray NS; Melnick A
    J Clin Invest; 2018 Oct; 128(10):4397-4412. PubMed ID: 30024860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.
    Nagel D; Spranger S; Vincendeau M; Grau M; Raffegerst S; Kloo B; Hlahla D; Neuenschwander M; Peter von Kries J; Hadian K; Dörken B; Lenz P; Lenz G; Schendel DJ; Krappmann D
    Cancer Cell; 2012 Dec; 22(6):825-37. PubMed ID: 23238017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
    Asaba KN; Adachi Y; Tokumaru K; Watanabe A; Goto Y; Aoki T
    Bioorg Med Chem Lett; 2021 Jun; 41():127996. PubMed ID: 33775836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peptide-based covalent inhibitors of MALT1 paracaspase.
    Hatcher JM; Du G; Fontán L; Us I; Qiao Q; Chennamadhavuni S; Shao J; Wu H; Melnick A; Gray NS; Scott DA
    Bioorg Med Chem Lett; 2019 Jun; 29(11):1336-1339. PubMed ID: 30954428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BEBT-908: A novel potent PI3K/HDAC inhibitor against diffuse large B-cell lymphoma.
    Li J; Qian C; Zhou Q; Li J; Li K; Yi P
    Biochem Biophys Res Commun; 2017 Sep; 491(4):939-945. PubMed ID: 28756223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An allosteric MALT1 inhibitor is a molecular corrector rescuing function in an immunodeficient patient.
    Quancard J; Klein T; Fung SY; Renatus M; Hughes N; Israël L; Priatel JJ; Kang S; Blank MA; Viner RI; Blank J; Schlapbach A; Erbel P; Kizhakkedathu J; Villard F; Hersperger R; Turvey SE; Eder J; Bornancin F; Overall CM
    Nat Chem Biol; 2019 Mar; 15(3):304-313. PubMed ID: 30692685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of new Malt1 inhibitors and probes.
    Xin BT; Schimmack G; Du Y; Florea BI; van der Marel GA; Driessen C; Krappmann D; Overkleeft HS
    Bioorg Med Chem; 2016 Aug; 24(15):3312-29. PubMed ID: 27085674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.